SEC Form 4 · accession 0001437749-19-002263
LIFECORE BIOMEDICAL, INC. \DE\ · LFCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nelson Obus
Director
Period of report
Feb 7, 2019
Accepted (ET)
Feb 11, 2019 · 8:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005286
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F1 | Feb 7, 2019 | P | 7,900 | $12.10 | A | 2,730,300 | I | By Wynnefield Capital, Inc. |
| Common StockF1 | Feb 8, 2019 | P | 5,000 | $12.15 | A | 2,735,300 | I | By Wynnefield Capital, Inc. |
| Common StockF1 | holding | — | — | — | 25,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all the reported shares for the purposes of Section 16 or for any other purpose.
- F2The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.